Alexandria Venture Investments returned for a series B round that increased the precision oncology drug developer's overall funding to over $150m.

US-based cancer therapy developer Boundless Bio completed a $105m series B round that included Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities. Investment management firm RA Capital Management and VC firm Nextech Invest co-led round, which also featured investment and financial services group Fidelity Management…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.